PMC7472830_01
Courses of the patient's treatments. (A) Changes of alpha-fetoprotein (AFP) level during each period. (B) Representative hepatic magnetic resonance (T2 weighted) assessments during each period. Red arrows indicate the tumors.
fimmu-11-02076-g001.jpg
PMC7472830_01_fimmu-11-02076-g001.jpg
F1
The patient's alpha-fetoprotein (AFP) level decreased to 40.4 mug/L from a baseline level of 9829.9 mug/L (Figure 1A). Magnetic resonance imaging (MRI) showed that the tumor nodule in the liver had shrunk dramatically with a response evaluation of partial regression (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (Figure 1B). AFP level (Figure 1A). And the patient's plasma glucose level was stable during follow-up visits.
Changes of fasting plasma glucose level during the hospital stay because of diabetic ketoacidosis.
fimmu-11-02076-g002.jpg
PMC7472830_01_fimmu-11-02076-g002.jpg
F2
The patient's plasma glucose returned to normal levels gradually and he was discharged 10 days later (Figure 2).